ERBB2 and lung cancer: Ideally in vitro functional assays need to be adapted to any type of molecular alteration including gene amplifications (known to be driver alterations such as ERBB2 in breast cancer), translocations (such as ALK in lung cancer), and deletions of tumor suppressor genes (such as PTEN).